• Nenhum resultado encontrado

Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs

N/A
N/A
Protected

Academic year: 2019

Share "Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs"

Copied!
7
0
0

Texto

Loading

Imagem

TABLE II
Fig. 1: representative isobolograms of in vitro interactions of calcium channel blockers (CCBs) and the partner drug against Leishmania (Leish- (Leish-mania) chagasi promastigotes
Fig. 2: representative isobolograms of in vitro interactions of calcium channel blockers (CCBs) and the partner drug against Leishmania (Leish- (Leish-mania) chagasi intracellular amastigotes

Referências

Documentos relacionados

The control of hypertension using monotherapy was more frequently attained in patients taking calcium channel blockers (80%) and beta blockers (71%), in comparison with those

OBJECTIVES: Primary objective: To quantify the beneits and harms of the major irst-line anti-hypertensive drug classes: thiazides, beta-blockers, calcium channel blockers,

Objective: To evaluate the efect of using antihypertensive classes of drugs of the calcium channel antagonists and inhibitors of angiotensin-converting enzyme in plasma

The present study, which endeavoured to assess the anti-leishmanial effect of a specific TSPO ligand in vitro , found that treatment with PK11195 reduced, in a time-

triphylla to allow the studies on this extremely rare species and even if appropriate reintroduction in the natural habitat to promote in situ conservation.. triphylla

In solutions with physiological concentration of calcium in the reperfusion solution, the calcium channel blockers offer little protection to the paradox, suggesting that more

-channel antago- nists in the management of clinical pain has also been somewhat controversial, especially regarding the effects of L-type antagonists.. An earlier study on this

Lovastatin (administered 1 h prior to carrageenan), at oral doses of 2, 5, and 10 mg/kg, markedly attenuated paw edema formation in rats at the 4th hour after carrageenan